Abstract: Post-market real-world data demonstrating use of an AI system as an extra reader to augment breast cancer detection without unnecessary recalls
Presented at ECR 2022
Purpose
To demonstrate real-world post-market benefit of artificial intelligence (AI) as an extra reader in breast cancer screening (BCS).
Method
A commercially available AI system was employed as an extra reader (XR) in addition to standard double reading (DR) at a BCS provider in Hungary from Apr-Sept 2021. The XR workflow involved flagging cases the AI suggested to recall which DR did not recall, i.e. positive discordant cases, for arbitration by an experienced radiologist. Detected cancers were pathology-confirmed.
Results
Standard DR for 3746 patients had an arbitration rate of 3.0% (114 patients), a recall rate of 6.7% (250 patients), and a cancer detection rate (CDR) of 12.5/1000 (47 cancer cases). Of the cases that were not recalled by DR, the AI flagged 396 cases to recommend recall (positive discordance rate 10.6%). Extra arbitration resulted in recalling 6 patients, all of whom were diagnosed with breast cancer. This equated to a total arbitration rate of 13.6% and 1.6/1000 increase in CDR (sum 14.1/1000). An exact simulation with a less sensitive AI operating point yielded a total arbitration rate of 5.3%, while still detecting 5 of 6 extra cancer cases.
Conclusion
This real-world deployment of AI increased cancer detection rates without recalling extra false positives, indicating the effectiveness of AI as extra reader. Combining the XR workflow with workflows focused on workload savings will mitigate the increased arbitration rate and optimise clinical and operational benefits. The results provide important, real-world evidence showing the benefit of using an AI reader in breast cancer screening, paving the way for innovative workflows where synergy of humans and AI achieve optimal performance for patients.
Limitation
Single-centre analysis; Only one extra arbitration reader was included.
Ethics committee approval
Not required.
Funding for this study
Kheiron Medical Technologies
PR
21st March 2024
12% more breast cancers detected with potential workload savings of 30% in the UK’s first prospective evaluation of breast screening AI
“It’s a lifesaver, it’s a life changer,” says one of the first women in the UK to have her breast cancer picked up by Kheiron Medical’s technology called Mia® An artific...
Read more
Abstract
4th January 2023
Abstract: Post-market real-world data demonstrating use of an AI system as an extra reader to augment breast cancer detection without unnecessary recalls
Purpose To demonstrate real-world post-market benefit of artificial intelligence (AI) as an extra reader in breast cancer screening (BCS). Method A commercially available AI system...
Read more
Abstract
4th January 2023
Abstract: Safe and effective integration of AI as supporting reader in double reading breast cancer screening
Purpose To evaluate the effectiveness and practical implications of a novel workflow of using AI as a supporting reader for the detection of breast cancer in double reading screeni...
Read more
Abstract
4th January 2023
Abstract: On the importance of including unconfirmed cases when assessing the effect of AI on the recall rate in breast cancer screening
Purpose To demonstrate the importance of using representative data, including unconfirmed cases (neither positive nor negative) to assess recall rate (RR) and avoid obscuring real-...
Read more
PR
28th November 2022
NHS Grampian is working with Kheiron Medical Technologies, University of Aberdeen and Microsoft to support breast cancer detection
NHS Grampian, which provides health and social care services to more than 500,000 people in Scotland, is trialling Kheiron Medical Technologies’ artificial intelligence to help ...
Read more
PR
28th November 2022
Gateshead Health Foundation NHS Trust furthers its partnership with Kheiron Medical Technologies under the NHS AI in Health & Care Award
In October 2021, Gateshead Health Foundation NHS Trust entered into a research agreement with Kheiron Medical Technologies as part of the NHS Artificial Intelligence (AI) in Health...
Read more
PR
11th May 2022
Kheiron Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women’s Health
Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel are trailblazers at the forefront of introducing innovative breast imaging technologies into clinical practice (London ...
Read more
PR
4th May 2022
InHealth signs up to AI Award with Kheiron
InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in...
Read more
PR
9th March 2022
Kheiron included in Fast Company’s Most Innovative Companies 2022 list
This AI cancer diagnostics company joins the ranks of Canva, Microsoft, SpaceX, and other winning companies that are changing lives for the better (London – March 9, 20...
Read more